scholarly journals Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase II a open‐label trial and subsequent phase III open‐label extension

2019 ◽  
Vol 182 (1) ◽  
pp. 85-96 ◽  
Author(s):  
M.J. Cork ◽  
D. Thaçi ◽  
L.F. Eichenfield ◽  
P.D. Arkwright ◽  
T. Hultsch ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Phase Ii ◽  
Phase Iii ◽  
Severe Atopic Dermatitis ◽  
Open Label ◽  
Open Label Extension ◽  
Subsequent Phase ◽  
Open Label Trial

scholarly journals Experience of patisiran with transthyretin stabilizers in patients with hereditary transthyretin-mediated amyloidosis

2020 ◽  
Vol 10 (5) ◽  
pp. 289-300 ◽  
Author(s):  
Hollis Lin ◽  
Madeline Merkel ◽  
Cecilia Hale ◽  
Jing L Marantz
Keyword(s):  
Quality Of Life ◽  
Diabetic Neuropathy ◽  
Phase Ii ◽  
Phase Iii ◽  
Open Label ◽  
Safety And Efficacy ◽  
Impairment Score ◽  
Open Label Extension ◽  
Post Hoc

Aim: Examine safety and pharmacodynamics of patisiran alone or with concomitant transthyretin stabilizers from the Phase II open-label extension study and safety and efficacy of patisiran in patients with prior transthyretin stabilizer use from the Phase III APOLLO study. Patients & methods: Post hoc analyses in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Results: Patisiran safety was consistent regardless of concomitant or prior transthyretin stabilizers. In the Phase II open-label extension (n = 27), transthyretin reduction was similar over 24 months, regardless of concomitant transthyretin stabilizers. In APOLLO (n = 225), patisiran-treated groups showed stabilization or improvements in neurological function (modified Neuropathy Impairment Score +7) and quality of life (Norfolk Quality of Life-Diabetic Neuropathy questionnaire) at 18 months, regardless of prior transthyretin stabilizers. Conclusion: Patients benefit from patisiran regardless of transthyretin stabilizer use.

16089 Safety of ATI-502, a novel topical JAK1/3 inhibitor, in adults with moderate to severe atopic dermatitis: Results from a phase 2a open-label trial

2020 ◽  
Vol 83 (6) ◽  
pp. AB170
Author(s):  
Stacy Smith ◽  
Neal Bhatia ◽  
Stuart D. Shanler ◽  
Rebecca DeMoor ◽  
Judith Schnyder
Keyword(s):  
Atopic Dermatitis ◽  
Severe Atopic Dermatitis ◽  
Open Label ◽  
Open Label Trial

26313 Efficacy and safety of dupilumab for up to 1 year in a phase 3 open-label extension (OLE) trial (LIBERTY AD PED-OLE) in adolescents with uncontrolled, moderate-to-severe atopic dermatitis (AD)

2021 ◽  
Vol 85 (3) ◽  
pp. AB97
Author(s):  
Andrew Blauvelt ◽  
Emma Guttman-Yassky ◽  
Amy S. Paller ◽  
Eric L. Simpson ◽  
John Browning ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Severe Atopic Dermatitis ◽  
Efficacy And Safety ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Extension

27424 Infections in adults with moderate-to-severe atopic dermatitis treated with dupilumab: long-term data from an open-label extension (OLE) study

2021 ◽  
Vol 85 (3) ◽  
pp. AB143
Author(s):  
Andrew Blauvelt ◽  
Andreas Wollenberg ◽  
Lawrence Eichenfield ◽  
Zhen Chen ◽  
Debra Sierka ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Severe Atopic Dermatitis ◽  
Open Label ◽  
Open Label Extension ◽  
Term Data

scholarly journals Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

2021 ◽  
Author(s):  
Eric L. Simpson ◽  
Jonathan I. Silverberg ◽  
Audrey Nosbaum ◽  
Kevin L. Winthrop ◽  
Emma Guttman-Yassky ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Atopic Dermatitis ◽  
Phase Ii ◽  
Safety Analysis ◽  
Phase Iii ◽  
Severe Atopic Dermatitis ◽  
Phase Iii Clinical Trial ◽  
Clinical Trial Program

27419 Laboratory safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension (OLE) study

2021 ◽  
Vol 85 (3) ◽  
pp. AB142
Author(s):  
Andrew Blauvelt ◽  
Andreas Wollenberg ◽  
Lisa A. Beck ◽  
Zhen Chen ◽  
Meng Zhang ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Severe Atopic Dermatitis ◽  
Laboratory Safety ◽  
Open Label ◽  
Open Label Extension
Sign in / Sign up

Export Citation Format

Share Document